What Are Analysts Suggestions On Allergan plc (AGN)

Cornelia Mascio
Novembre 18, 2017

A statistical measure of the dispersion of returns (volatility) for AGN producing salvation in Investors mouth, it has week volatility of 2.34% and for the month booked as 3.06%. They are projecting Next Quarter growth of 10.1%. Jacobi Capital Management LLC now owns 472 shares of the company's stock valued at $112,000 after purchasing an additional 22 shares in the last quarter. Equity analyst Royal Bank Of Canada lowered the price target of the stock on November 2 changing the price objective from $250.00 to $221.00 with a rating of "Outperform". If you are accessing this piece on another domain, it was illegally copied and reposted in violation of USA & global copyright legislation.

Allergan plc (AGN) closed -23.27% below its 200-day moving average and is -11.75% below another chart threshold, its 50-day moving average. Pathstone Family Office LLC raised its stake in shares of Allergan PLC.by 3,327.3% during the second quarter.

Allergan plc (NYSE:AGN) tumbled -16.76% year-to-date. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.18 and a quick ratio of 1.08. Institutional investors and hedge funds own 81.21% of the company's stock. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have assigned a buy rating to the company's stock. Finally, Trust Co lifted its stake in Allergan PLC.by 0.8% during the first quarter. The company reported $4.15 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $4.06 by $0.09. JNBA Financial Advisors now owns 487 shares of the company's stock worth $116,000 after acquiring an additional 12 shares in the last quarter.

Allergan plc (NYSE:AGN) shares were trading higher by 0.72 percent ($1.23) at $173.05 a piece in Wednesday's session. Analysts reported that the Price Target for Allergan plc might touch $280 high while the Average Price Target and Low price Target is $233 and $191 respectively. 2,819,104 shares of the company were exchanged, compared to its average volume of 2,909,661. BidaskClub lowered shares of Allergan PLC. from a "buy" rating to a "hold" rating in a research note on Wednesday, August 9th. Allergan plc's institutional ownership is 85.3%, while its institutional transactions stand at -1.31%.

The average 1-year price target for Allergan plc (AGN) - averaging the work of different analysts - reveals a mean PT of $233/share. Allergan plc (NYSE:AGN) has consensus analyst target price is $230.78. The company has a market cap of $71.62 billion, a PE ratio of 5.35 and a beta of 1.01. Wells Fargo & Company's price target suggests a potential upside of 40.10% from the stock's previous close. High Point Bank & Trust Co. now owns 692 shares of the company's stock worth $160,000 after buying an additional 115 shares during the period.

Allergan PLC. announced that its board has initiated a share repurchase plan on Monday, September 25th that authorizes the company to repurchase $2.00 billion in shares. Allergan plc experienced its Day High at -27.11%, with its Day Low of 2.03%.

The performance week demonstrated a value of -1.12%. The authority will not be accountable for anyone who makes stock portfolio or financial decisions as per this reporting, which has been constructed only on limited and open source information. The ROA for Allergan plc tells us exactly what earnings were generated from the invested capital. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE